Blends mix BPC-157, TB-500 and GHK-Cu. The mixtures are untested in people

A blend combines several peptides in one vial. A typical recovery blend contains BPC-157 and TB-500, often with the copper peptide GHK-Cu; some add KPV. The thinking is that peptides with different proposed mechanisms might work better together.

That idea has not been tested in a trial. Each ingredient has its own evidence, and most of it is from animals. A 2025 systematic review of BPC-157 found 35 preclinical studies and one clinical report. KPV’s best-known result is in mice with inflamed bowels. GHK-Cu has decades of lab work and small studies of skin creams, not injections.

TB-500 is a short fragment of thymosin beta-4. The full-length protein has been tested in people, but as eye drops. In a 2015 phase 2 trial in 72 people with dry eye, the drops missed both main goals, while some secondary measures improved: discomfort in one test was 27% lower than on placebo. That says little about an injected fragment.

The only human data on a combination we found is tiny. In a 2021 chart review from a Florida clinic, four people received knee injections of BPC-157 together with thymosin beta-4, and three reported significant pain relief. There was no comparison group.

Mixing raises questions that single-ingredient research doesn’t answer: whether the peptides stay stable together, how the amount of each is checked, and whether side effects add up. A 2026 sports-medicine review warned that for these gray-market peptides “rigorous human safety data are scarce, and there is potential for serious harm”.

Read each ingredient’s profile before reading a blend label. Research blends are listed separately in the research shop; they are laboratory materials, not tested treatments.